We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Esperion (ESPR) Offers Updates on LDL-Lowering Candidate
Read MoreHide Full Article
Esperion Therapeutics, Inc. (ESPR - Free Report) announced updates on a clinical development program as well as its regulatory plans for lead candidate, bempedoic acid (ETC-1002), for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
The program includes pivotal phase III efficacy and safety studies, and a planned global cardiovascular outcomes trial (CVOT) in patients with elevated LDL-C levels who are unable to tolerate statins (statin intolerance).
These studies are expected to be initiated in the fourth quarter of 2016. While the pivotal phase III efficacy studies will assess patients with elevated LDL-C levels, including statin intolerant patients, the CVOT will evaluate the candidate in statin intolerant patients who are at high risk of cardiovascular (CV) diseases.
Esperion stated that the planned efficacy studies and the ongoing long-term safety and tolerability study (1002-040) will support the submission of a marketing application for bempedoic acid in patients with elevated LDL-C, including statin-intolerant patients in the EU in 2019. In addition, the CVOT will support the submission of a regulatory application for risk reduction of CV diseases in statin-intolerant patients in the EU in 2022.
However, the FDA has not provided any clarity on a regulatory pathway for an LDL-C lowering indication in statin-intolerant patients. Esperion plans to submit a New Drug Application (NDA) in the U.S. for a CV risk reduction indication on the basis of the successful completion of the CVOT in 2022.
Meanwhile, Esperion provided an update on its financial outlook for 2016. Full-year net cash used in operating activities are expected in the range $65–$75 million (previous expectations: $80–$90 million). Cash and cash equivalents and investment securities are expected to be approximately $220 million (prior guidance: $200 million) at Dec 31, 2016.
We remind investors that the cholesterol management market is presently dominated by drugs such as Praluent, Repatha, Mevacor and Pravachol among others.
Esperion currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Bristol-Myers Squibb Company (BMY - Free Report) and Pfizer Inc. (PFE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Esperion (ESPR) Offers Updates on LDL-Lowering Candidate
Esperion Therapeutics, Inc. (ESPR - Free Report) announced updates on a clinical development program as well as its regulatory plans for lead candidate, bempedoic acid (ETC-1002), for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
The program includes pivotal phase III efficacy and safety studies, and a planned global cardiovascular outcomes trial (CVOT) in patients with elevated LDL-C levels who are unable to tolerate statins (statin intolerance).
These studies are expected to be initiated in the fourth quarter of 2016. While the pivotal phase III efficacy studies will assess patients with elevated LDL-C levels, including statin intolerant patients, the CVOT will evaluate the candidate in statin intolerant patients who are at high risk of cardiovascular (CV) diseases.
Esperion stated that the planned efficacy studies and the ongoing long-term safety and tolerability study (1002-040) will support the submission of a marketing application for bempedoic acid in patients with elevated LDL-C, including statin-intolerant patients in the EU in 2019. In addition, the CVOT will support the submission of a regulatory application for risk reduction of CV diseases in statin-intolerant patients in the EU in 2022.
However, the FDA has not provided any clarity on a regulatory pathway for an LDL-C lowering indication in statin-intolerant patients. Esperion plans to submit a New Drug Application (NDA) in the U.S. for a CV risk reduction indication on the basis of the successful completion of the CVOT in 2022.
Meanwhile, Esperion provided an update on its financial outlook for 2016. Full-year net cash used in operating activities are expected in the range $65–$75 million (previous expectations: $80–$90 million). Cash and cash equivalents and investment securities are expected to be approximately $220 million (prior guidance: $200 million) at Dec 31, 2016.
We remind investors that the cholesterol management market is presently dominated by drugs such as Praluent, Repatha, Mevacor and Pravachol among others.
Esperion currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Bristol-Myers Squibb Company (BMY - Free Report) and Pfizer Inc. (PFE - Free Report) , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>